SEC Comment Letter 0000000000-23-009115 to X4 Pharmaceuticals, Inc (XFOR)
X4 Pharmaceuticals, Inc
Date: Aug. 21, 2023 · CIK: 0001501697 · Accession: 0000000000-23-009115
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-273961
Letter
United States securities and exchange commission logo August 21, 2023 Adam Mostafa Chief Financial Officer and Treasurer X4 Pharmaceuticals, Inc 61 North Beacon Street, 4th Floor Boston, MA 02134 Re:X4 Pharmaceuticals, Inc Registration Statement on Form S-3 Filed August 14, 2023 File No. 333-273961 Dear Adam Mostafa: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Daniel I. Goldberg, Esq.
Show Raw Text
United States securities and exchange commission logo
August 21, 2023
Adam Mostafa
Chief Financial Officer and Treasurer
X4 Pharmaceuticals, Inc
61 North Beacon Street, 4th Floor
Boston, MA 02134
Re:X4 Pharmaceuticals, Inc
Registration Statement on Form S-3
Filed August 14, 2023
File No. 333-273961
Dear Adam Mostafa:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Daniel I. Goldberg, Esq.